Maternal-fetal outcomes of women with hypertensive disorders of pregnancy

Abstract

SUMMARY OBJECTIVE: The objective of this study was to determine adverse maternal and perinatal outcomes in pregnant women with hypertensive disorders of pregnancy. METHODS: An analytical cross-sectional study was conducted on women admitted with hypertensive disorders of pregnancies to a university maternity hospital from August 2020 to August 2022. Data were collected using a pretested structured questionnaire. Variables associated with adverse maternal and perinatal outcomes were compared using multivariable binomial regression. RESULTS: Of 501 women with pregnancies, 2, 35, 14, and 49% had eclampsia, preeclampsia, chronic hypertension, and gestational hypertension, respectively. Women with preeclampsia/eclampsia had significantly higher risks of cesarean section (79.4 vs. 65%; adjusted RR, 2,139; 95%CI, 1,386–3,302; p=0.001) and preterm delivery at <34 weeks’ gestation (20.5 vs. 6%; adjusted RR, 2.5; 95%CI, 1.19–5.25; p=0.01) than those of women with chronic/gestational hypertension. Risks of prolonged maternal hospitalization (43.9 vs. 27.1%), neonatal intensive care unit admission (30.7 vs. 19.8%), and perinatal mortality (23.5 vs. 11.2%) were higher among women with preeclampsia/eclampsia. CONCLUSIONS: Women with preeclampsia/eclampsia had a higher risk of adverse maternal and neonatal outcomes than those with chronic or gestational hypertension. This major maternity care center requires strategies for preventing and managing preeclampsia/eclampsia to improve pregnancy outcomes.

Could signal peptide complement C1r/C1s, Uegf, and Bmp1, and epidermal growth factor-containing protein 1 be a therapeutic target in the pathogenesis of preeclampsia?

“…Preeclampsia is one of the most important causes of maternal and perinatal mortality and morbidity all over the world 1 . Preeclampsia is a serious pregnancy-specific hypertensive disease that presents with various organ failures, especially dysfunction of the kidneys, liver, and lungs 2 . Currently, the only known definitive treatment for preeclampsia is to terminate the pregnancy and deliver the newborn 3 , 4 .…”

Comment on “Maternal-fetal outcomes of women with hypertensive disorders of pregnancy”

“…We read with great interest the recent study 1 investigating the maternal-fetal outcomes of women with hypertensive disorders during pregnancy. This study offers valuable insights into the impact of these disorders on both expectant mothers and their unborn children.…”

“…It elucidated the complex ways in which these disorders can affect maternal health, underscoring the necessity for heightened monitoring and care during pregnancy. Furthermore, the study 1 demonstrates the consequences for fetal outcomes, presenting a thorough overview of the potential challenges that may arise. It explored factors such as prematurity birth <34 weeks, NICU admission, and perinatal mortality, offering a holistic understanding of these disorders.…”

“…First, as described in the study 1 , the subjects of this research were women with hypertensive disorders during pregnancy, with 316 having hypertension. Clearly, for this subgroup of hypertensive patients, the absence of treatment strategies for hypertension is evident.…”